Business
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
PLYMOUTH MEETING, Pa., April 16, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL.
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4113,"height":1051,"url":"https://media.zenfs.com/en/business-wire.com/0777516d125c1d6f4dfa886616c5fb71"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jzYlIke0.MUSoXei3iIw3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NQ--/https://media.zenfs.com/en/business-wire.com/0777516d125c1d6f4dfa886616c5fb71","width":960,"height":245},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YRM37Y7WPoEi9ay4elE6bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MTQ-/https://media.zenfs.com/en/business-wire.com/0777516d125c1d6f4dfa886616c5fb71","width":1200,"height":307}},"lazy":false},{"type":"text","content":"PLYMOUTH MEETING, Pa., April 16, 2026--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL.","length":415,"tagName":"p"},{"type":"text","content":"The ARGUS trial is currently enrolling, and more information about the trial can be found at argustrial.com.","length":108,"tagName":"p"},{"type":"text","content":"Poster presentation details are listed below:","length":45,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;width:11%;","val":[{"type":"text","content":"Abstract Title:","length":15,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"width:1%;","val":[]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;width:88%;","val":[{"type":"text","content":"ARGUS: A Study of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Participants with Dravet Syndrome (DS): Preliminary Results from the Open-label Extension Phase","length":172,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"padding-left:0.0px;","val":[]},{"colspan":"1","rowspan":"1","style":"padding-left:0.0px;","val":[]},{"colspan":"1","rowspan":"1","style":"padding-left:0.0px;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan"...